Home World News Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or... World News Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 972 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Excellence in cancer research nursing: Celebrating innovation during tough times October 7, 2022 En gran cantidad de casos el exito o examen experto os... August 21, 2023 Apple Season is Here! October 1, 2021 Rediscovered Drugs Hit Leukemia from Two Different Angles July 21, 2020 Load more HOT NEWS Cancer target missed for 55,000 patients over 6 years Spring Budget 2023: What does it mean for the mission to... Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... How can we diagnose more cancers earlier?
